DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 078411
NDA 078411 describes DIVALPROEX SODIUM, which is a drug marketed by Dr Reddys Labs Ltd, Mylan, Zydus Pharms Usa Inc, Actavis Labs Fl Inc, Anchen Pharms, Aurobindo Pharma Ltd, Lupin, Nu Pharm, Orchid Hlthcare, Prinston Inc, Sandoz, Sun Pharm Inds, Teva, Unichem Labs Ltd, Upsher-smith Labs, Wockhardt, Amneal Pharms, G And W Labs Inc, Impax Labs, and Reddys, and is included in thirty NDAs. It is available from thirty-eight suppliers. Additional details are available on the DIVALPROEX SODIUM profile page.
The generic ingredient in DIVALPROEX SODIUM is divalproex sodium. There are seventeen drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the divalproex sodium profile page.
The generic ingredient in DIVALPROEX SODIUM is divalproex sodium. There are seventeen drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the divalproex sodium profile page.
Summary for 078411
| Tradename: | DIVALPROEX SODIUM |
| Applicant: | Anchen Pharms |
| Ingredient: | divalproex sodium |
| Patents: | 0 |
| Therapeutic Class: | Anticonvulsants Antimigraine Agents Bipolar Agents |
| Formulation / Manufacturing: | see details |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, DELAYED RELEASE;ORAL | Strength | EQ 500MG VALPROIC ACID | ||||
| Approval Date: | Nov 3, 2008 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
